



Treatment of HIV Infection: Strategies, New Drugs and Drug Metabolism

Guest Editor:

Dr. Salvatore Martini

Infectious Disease Unit,
University Hospital Luigi
Vanvitelli, Naples, Italy

Deadline for manuscript
submissions:

28 February 2025

Message from the Guest Editor

Dear Colleagues,

HIV is one of the most important infectious diseases due to its clinical and sociological implications, as patients still face stigma, and its wide diffusion, despite long-standing awareness and prevention campaigns. Research has made many advancements to improve not only treatment effectiveness but also patient quality of life. Nowadays, therapies are based on single-tablet regimens, reducing the pill burden. Additionally, there is also the revolutionary possibility of resorting to long-acting injection therapy, administered every two months. In fact, this could guarantee patients greater freedom around therapy, avoiding taking daily drugs, which could further translate, for some, into logistical and sometimes psychological advantages. This Special Issue aims to analyze the effect of this type of regimen on patients in terms of efficacy and metabolism.

Dr. Salvatore Martini

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding

Rehabilitation Hospital and

Massachusetts General Hospital,

Harvard Medical School, Boston,

MA 02114, USA

2. Department of Epidemiology,

Harvard T.H. Chan School of

Public Health, Boston, MA 02115,

USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)